Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.62 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.50 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.50 |
| ▸ | SCD5 | Q86SK9 | 3/20 | 0.50 |
| ▸ | SCD | O00767 | 1/20 | 0.50 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27574934 | 1.00 | RIPK1 (0.62) | RIPK1HSD11B1HSP90AA1HSP90AB1EPHX2 | |
| SCHEMBL27574946 | 1.00 | RIPK1 (0.62) | RIPK1HSD11B1HSP90AA1HSP90AB1EPHX2 | |
| Water SCHEMBL27700791 | 0.98 | RIPK1 (0.60) | RIPK1HSD11B1HSP90AA1HSP90AB1EPHX2 | |
| SCHEMBL1847627 | 0.95 | RIPK1 (0.69) | RIPK1HSD11B1HSP90AA1HSP90AB1EPHX2 | |
| SCHEMBL17558248 | 0.95 | RIPK1 (0.69) | RIPK1HSD11B1HSP90AA1HSP90AB1EPHX2 | |
| SCHEMBL1853141 | 0.95 | RIPK1 (0.69) | RIPK1HSD11B1HSP90AA1HSP90AB1EPHX2 | |
| SCHEMBL27659813 | 0.91 | RIPK1 (0.57) | RIPK1HSD11B1HSP90AA1HSP90AB1EPHX2 | |
| SCHEMBL535098 | 0.90 | RIPK1 (0.52) | RIPK1HSD11B1HSP90AA1HSP90AB1EPHX2 | |
| SCHEMBL4019469 | 0.89 | RIPK1 (0.62) | RIPK1HSD11B1HSP90AA1HSP90AB1EPHX2 | |
| SCHEMBL17026995 | 0.87 | RIPK1 (0.67) | RIPK1HSD11B1HSP90AA1HSP90AB1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739655-A2 | SUBSTITUTED 2-PHENYLPIPERIDINE COMPOUNDS FOR USE IN THE DIAGNOSIS, TREATMENT AND/OR PREVENTION OF CANCER | Nestor, Marika (SE) | 2026-05-13 | — | — | EP | claimed |
| WO-2025008409-A2 | SUBSTITUTED 2-PHENYLPIPERIDINE COMPOUNDS FOR USE IN THE DIAGNOSIS, TREATMENT AND/OR PREVENTION OF CANCER | JHA PREETI (US) | 2025-01-09 | — | — | WO | claimed |
| EP-2828253-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | Abide Therapeutics, Inc. (US) | 2015-01-28 | — | — | EP | claimed |
| WO-2013142307-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | ABIDE THERAPEUTICS (US) | 2013-09-26 | — | — | WO | claimed |
| EP-4551556-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | Vividion Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| EP-4313295-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | Almac Discovery Limited (GB) | 2024-02-07 | — | — | EP | disclosed |
| WO-2024010784-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| CN-117157285-A | Pharmaceutical compounds as ubiquitin-specific protease 19 (USP 19) inhibitors | 阿尔麦克探索有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-117043151-A | Pyrimidine or pyridine derivative and medical application thereof | 希格生科（深圳）有限公司 | 2023-11-10 | — | — | CN | disclosed |
| US-11661418-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| CN-116115618-A | Medicine for treating tumor | 石药集团中奇制药技术（石家庄）有限公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-115551859-A | Aza condensed ring amide compound and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2022-12-30 | — | — | CN | disclosed |
| WO-2010099054-A2 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20090186874-A1 | Carboxamide derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| CN-101296914-A | Derivatives with PPAR agonist activity | SHIONOGI & CO (JP) | 2008-10-29 | — | — | CN | disclosed |
| EP-1610786-B9 | 4-(4-(HETEROCYCLYLALKOXY PHENYL)-1-(HETEROCYCLYL-CARBONYL)PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H3 ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISEASES SUCH AS ALZHEIMER'S | GLAXO GROUP LTD (GB) | 2008-02-27 | — | — | EP | disclosed |
| EP-1610786-B1 | 4-(4-(HETEROCYCLYLALKOXY PHENYL)-1-(HETEROCYCLYL-CARBONYL)PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H3 ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISEASES SUCH AS ALZHEIMER'S | GLAXO GROUP LTD (GB) | 2007-06-20 | — | — | EP | disclosed |
| EP-1610786-A1 | 4-(4-(HETEROCYCLYLALKOXY PHENYL)-1-(HETEROCYCLYL-CARBONYL)PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H3 ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISEASES SUCH AS ALZHEIMER'S | GLAXO GROUP LIMITED (GB) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004089373-A1 | 4- (4-(HETEROCYCLYLALKOXY}PHENYL)-1-(HETEROCYCLYL-CARBONYL)PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H3 ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISEASES SUCH AS ALZHEIMER’S | GLAXO GROUP LIMITED (GB) | 2004-10-21 | — | — | WO | disclosed |
| CN-1432011-A | Benzoamide piperidine compounds as substance P antagonists | PFIZER PROD INC (US) | 2003-07-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186874-A1 | Carboxamide derivative and use thereof | NTSR2, NTSR1, CNR2 | RIPK1 2706/4885HSD11B1 2434/4885HSP90AA1 4846/4885 |
| US-11661418-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | RIPK1 1808/4885HSD11B1 4319/4885HSP90AA1 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.